Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KROS | US
-0.41
-0.67%
Healthcare
Biotechnology
30/06/2024
04/10/2024
60.90
60.21
61.33
59.49
Keros Therapeutics Inc. a clinical-stage biopharmaceutical company discovers develops and commercializes novel treatments for patients suffering from hematological pulmonary and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050 which is being developed for the treatment of low blood cell counts or cytopenias including anemia and thrombocytopenia in patients with myelodysplastic syndromes as well as in patients with myelofibrosis. It also develops KER-047 a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012 which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics Inc. was incorporated in 2015 and is headquartered in Lexington Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
33.2%1 month
45.5%3 months
49.1%6 months
47.5%-
-
5.03
0.03
0.03
-13.05
6.37K
-
-187.62M
2.30B
2.30B
-
-136.32K
-
-
-44.98
10.09
13.07
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
8.03
Range1M
13.98
Range3M
20.75
Rel. volume
0.67
Price X volume
17.21M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
ACADIA Pharmaceuticals Inc | ACAD | Biotechnology | 15.1 | 2.50B | -0.20% | 82.58 | 11.16% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Structure Therapeutics Inc. American Depositary Shares | GPCR | Biotechnology | 42.99 | 2.46B | -1.15% | n/a | 0.51% |
SPRINGWORKS THERAPEUTICS INC. | SWTX | Biotechnology | 32.64 | 2.42B | -0.58% | n/a | 1.27% |
IBRX | IBRX | Biotechnology | 3.43 | 2.39B | -3.92% | n/a | -143.04% |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 40.84 | 2.35B | -2.18% | n/a | 16.11% |
Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 45.02 | 2.35B | 3.61% | n/a | 3.62% |
Arrowhead Pharmaceuticals Inc | ARWR | Biotechnology | 18.82 | 2.34B | -2.08% | n/a | 137.39% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -13.05 | 0.76 | Cheaper |
Ent. to Revenue | 6,369.80 | 3,674.48 | Expensive |
PE Ratio | - | 38.01 | - |
Price to Book | 5.03 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 49.09 | 74.67 | Lower Risk |
Debt to Equity | 0.03 | -1.82 | Expensive |
Debt to Assets | 0.03 | 0.26 | Cheaper |
Market Cap | 2.30B | 3.73B | Emerging |